GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (NAS:GALT) » Definitions » Net Income (Continuing Operations)

GALT (Galectin Therapeutics) Net Income (Continuing Operations) : $-45.08 Mil (TTM As of Sep. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Galectin Therapeutics Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Galectin Therapeutics's Net Income (Continuing Operations) for the three months ended in Sep. 2024 was $-11.22 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2024 was $-45.08 Mil.

Galectin Therapeutics Net Income (Continuing Operations) Historical Data

The historical data trend for Galectin Therapeutics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics Net Income (Continuing Operations) Chart

Galectin Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.29 -23.47 -30.53 -38.78 -41.07

Galectin Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.43 -10.00 -11.49 -12.37 -11.22

Galectin Therapeutics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galectin Therapeutics  (NAS:GALT) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Galectin Therapeutics Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Galectin Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (NAS:GALT) » Definitions » Net Income (Continuing Operations)
Comparable Companies
FULC ACTU NKTX MDWD VSTM GLSI ZURA TIL ADAP INZY VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
PHPN:Germany
Address
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Website
https://www.galectintherapeutics.com
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Executives
Kary Eldred director 2121 RINGWOOD AVENUE, SAN JOSE CA 95131
Kevin D Freeman director 712 LAKEWAY DRIVE, KELLER TX 76248
Zordani Richard A. Jr. director 467 N. COUNTRY RIDGE CT., LAKE ZURICH IL 60047
Joel Lewis director 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
James C Czirr director 4908 SOUTH ASHTON COURT, SPOKANE WA 99223
10x Fund, L.p. 10 percent owner 1099 FOREST LAKE TERRACE, NICEVILLE FL 32578
Elissa J. Schwartz director 235 SW CHURCH ST., PULLMAN WA 99163
Gilbert F Amelio director 5835 STRASBOURG COURT, ---, RENO NV 89511
Richard E Uihlein director, 10 percent owner 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Pol F Boudes officer: Chief Medical Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Marc Rubin director C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Harold H. Shlevin director, officer: Chief Executive Officer C/O GALECTIN THERAPEUTICS, INC., 4690 PEACHTREE INDUSTRIAL BLVD, STE. 240, NORCROSS GA 30071
Jack W Callicutt officer: Chief Financial Officer 75 FIFTH STREET NW STE. 313, ATLANTA GA 30308
Peter G Traber director, officer: President and CEO 430 THAMER LANE, HOUSTON TX 77025